Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this cancer: (TITLE:"Non-Hodgkin lymphoma" OR ABSTRACT:"Non-Hodgkin lymphoma" OR TITLE:"all types" OR ABSTRACT:"all types" OR TITLE:"Non-Hodgkin Lymphoma" OR ABSTRACT:"Non-Hodgkin Lymphoma" OR TITLE:"NHL" OR ABSTRACT:"NHL" OR TITLE:"Non-Hodgkin's lymphoma" OR ABSTRACT:"Non-Hodgkin's lymphoma" OR TITLE:"Lymphoma non-Hodgkin" OR ABSTRACT:"Lymphoma non-Hodgkin") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Non-Hodgkin lymphoma (all types), not a curated reading list.
Anti-CD20 rituximab for relapsed follicular lymphoma; added to CHOP it raised cure rates in diffuse large B-cell lymphoma.
Axicabtagene ciloleucel approved for relapsed large B-cell lymphoma after two or more lines.
Glofitamab and epcoritamab, off-the-shelf CD20 x CD3 antibodies, approved for relapsed large B-cell lymphoma.